MedTrace Logo

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122486 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2006-08-01

No results posted yet for this study

Summary

This Phase 2 study involving tenofovir disoproxil fumarate (TDF) will assess the extended safety of TDF 300 mg per day among young women who are not HIV-infected.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir Disoproxil Fumarate

Sponsors & Collaborators

  • FHI 360

    lead OTHER

Principal Investigators

  • Leigh Peterson, PhD · FHI 360

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Completion
2006-03-31

Countries

  • Cameroon
  • Ghana
  • Nigeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122486 on ClinicalTrials.gov